Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPension (IS)Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Harvard Bioscience (HBIO) Shares Outstanding (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Shares Outstanding for 16 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.47% to $44.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $44.7 million through Dec 2025, up 1.47% year-over-year, with the annual reading at $44.7 million for FY2025, 1.47% up from the prior year.
  • Shares Outstanding for Q4 2025 was $44.7 million at Harvard Bioscience, roughly flat from $44.6 million in the prior quarter.
  • The five-year high for Shares Outstanding was $47.7 million in Q1 2021, with the low at $40.5 million in Q2 2021.
  • Average Shares Outstanding over 5 years is $43.0 million, with a median of $43.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding grew 3.41% in 2021, then decreased 13.53% in 2022.
  • Over 5 years, Shares Outstanding stood at $41.1 million in 2021, then grew by 2.28% to $42.1 million in 2022, then increased by 3.12% to $43.4 million in 2023, then grew by 1.56% to $44.1 million in 2024, then grew by 1.47% to $44.7 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $44.7 million, $44.6 million, and $44.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.